banda transcan 2 2016ul

TRANSCAN-3 has preannounced the first co-funded Joint Transnational Call for proposals JTC 2021

on the topic:

"Next generation cancer immunotherapy: targeting the tumour microenvironment"


LAUNCH DATE: April 6th, 2021


DEADLINE  for Stage 1 (pre-proposal submission): end of June 2021

STAGE 2: It is expected that consortia invited for full-proposal submission will be asked to submit their proposal on November 2021.


The following 28 funding organisations have agreed to participate in JTC 2021:

  • Austrian Science Fund (FWF), Austria
  • Research Foundation - Flanders (FWO), Belgium, Flanders
  • Fund for Scientific Research (F.R.S.-FNRS), Belgium, French speaking community
  • Canadian Institutes of Health Research (CIHR), Canada
  • Estonian Research Council (ETAg), Estonia
  • French National Cancer Institute (INCa), France
  • ARC French Foundation for Cancer Research (ARC Foundation), France
  • Federal Ministry of Education and Research (BMBF), Germany
  • National Research, Development and Innovation Office (NKFIH), Hungary
  • Health Research Board (HRB), Ireland
  • The Chief Scientist Office of the Ministry of Health (CSO-MOH), Israel
  • Ministry of Health (IT-MOH), Italy
  • Ministry of Universities and Research (MUR), Italy
  • Alliance Against Cancer (ACC), Italy
  • Tuscany Region (TuscReg), Tuscany, Italy
  • Fondazione Regionale per la Ricerca Biomedica (FRRB), Lombardy, Italy
  • State Education Development Agency (VIAA), Latvia
  • Research Council of Norway (RCN), Norway
  • Norwegian Cancer Society (NCS), Norway
  • National Centre for Research and Development (NCBR), Poland
  • Foundation for Science and Technology (FCT), Portugal
  • Executive Agency for Higher Education, Research, Development and Innovation Funding (UEFISCDI), Romania
  • Slovak Academy of Sciences (SAS) , Slovakia
  • National Institute of Health Carlos III (ISCIII), Spain
  • The Scientific Foundation of the Spanish Association Against Cancer (FCAECC), Spain
  • The Foundation for the support of the Applied Scientific Research and Technology in Asturias (FICYT), Spain
  • Ministry of Science and Technology (MoST), Taiwan
  • The Scientific and Technological Research Council of Turkey (TÜBITAK), Turkey




ERA-NET Cofund TRANSCAN-3: Sustained collaboration of national and regional programmes in cancer research


For information about the project go to the TRANSCAN-3 website at:

The TRANSCAN-3 newsletters are published on the website, SUBSCRIBE to the newsletters
You can unsubscribe at any moment by clicking on the subscription preferences link at the bottom of a received newsletter

and follow us on social media: twitter logoinkedin social media logo



Projects funded under JTC 2017 on: "Translational research on rare cancers"

Harnessing BRCAness as a therapeutic target in high-risk pediatric solid tumors
Implementation of (epi)genetic and metabolic networks in the targeting of T-cell prolymphocytic leukemia
An integrated European platform to conduct translational studies in myelodysplastic syndromes based on the EuroBloodNet infrastructure
Translational Research in Peripheral T-Cell Lymphomas: from characterization to novel targets
Advancing liquid biopsies for monitoring and personalized treatment of children with neuroblastomas
Comprehensive genomic characterization of upper urinary tract urothelial carcinoma and paired bladder recurrences
Establishing an algorithm for the early diagnosis and follow-up of patients with pancreatic neuroendocrine tumors
Predictive models of therapy response in pancreatic neuroendocrine tumors
Profiling radioREsistant Differentiated thyroid Cancer: genes, immunity, cancer stem cells and epithelial-mesenchymal transition
Automated, absolute quantification of MRD in ALL patients by droplet microfluidics, single DNA copy barcoding and IG/TR amplicon NGS
Anti-PD1 and Niraparib (PARPi) combination therapy in gynae carcinosarcoma: Identification of response-predictive biomarkers and resistance mechanisms
A TranslatiOnal Platform for de-orphaning malignant pleural MESOthelioma


Projects funded under JTC 2016 on: "Minimally and non-invasive methods for early detection and/or progression of cancer"

Airborne biomarkers for colorectal cancers
Biomarkers for diagnosis and prognosis of endometrial carcinoma
Validation of multiparametric models and Circulating and imaging biomarkers to improve Lung cancer EARLY detection
Detection of early esophageal cancer by near-infrared fluorescence molecular endoscopy
Multi-parametric analysis of the evolution and progression of low grade glioma
Single-cell immunophenotypic and transcriptomic profiling for minimally-invasive detection of early multiple myeloma
New strategies to detect cancers in carriers of mutations in RB1: blood tests based on tumor-educated platelets, or extracellular vesicles
Employing NGS technology for improved, non-invasive early detection, staging and prediction of progression in lymphoma patients
Early detection of prostate cancer by liquid biopsies
Exploitation of extracellular vesicles for precision diagnostics of prostate cancer
Non-invasive prognostic markers for Resected Early-STage NSCLC: role of circulatING and exosomal miRNAs and free circulating DNA
Microbiota-based SCReening of Anal Cancer in HIV-infected individuals
Early detection of relapses in stage III colon cancer patients by longitudinally following a personalized molecular signature from a a blood test: THRuST
Integration of genetic biomarkers and early minimal residual disease to improve risk stratification and cure in childhood Acute Lymphoblastic Leukemia



Projects funded under JTC 2015 on: "Immunology and immunotherapy of cancer: strengthening the translational aspects"

Impact of dietary intervention on tumor immunity
Dual epigenetic targeting and immunotherapy to fight against cancer
Mutated neo-antigens in hepatocellular carcinoma
Deciphering immune response against glioblastoma to find new targets
Targeting sphingolipid metabolism to improve anti-melanoma immunotherapy
Improving immunotherapy of solid tumors by targeting the immunosuppressive tumor microenvironment: from pre-clinical "proof-of-concept" to the development of phase Ib study
Prediction of nivolumab action in metastatic renal cancer patients:Treg function, tumoral access and NK interactions as predictive biomarkers of immunotherapy




Projects funded under JTC 2014 (EC co-funded call) on: "Translational research on human tumour heterogeneity to overcome recurrence and resistance to therapy"

Approaching recurrence and resistance mechanisms in esophagogastric adenocarcinomas from the prospective MEMORI trial
Patient‐derived models for intratumour functional heterogeneity and its implications for personalized medicine
Clinical impact of intratumor heterogeneity in metastatic breast cancer
Cancer evolution and identification of relapse-initiating cells
Defeating Recurrence and resistance in AML:Multigenomic Approaches to analyse heterogeneity
Fighting Resistance in CLL
Genetic and cellular intratumor heterogeneity as predictor of chronic lymphocytic leukemia outcome and treatment resistance
Intratumour heterogeneity, clonal selection and metastatic propensity in breast cancer
Evolution of resistant clones to novel target-directed drugs in colorectal tumors. A genetic and epigenetic study of intratumoral  heterogeneity dynamics
Multiple myeloma intra-clonal heterogeneity: evolution and implications of targeted therapy
Dissecting phenotypic heterogeneity of human melanoma: building a rationale for active immunotherapies overcoming   immunologically-induced dedifferentiation
Overcoming Neuroblastoma Tumour HETerogeneity, Resistance and RecurrAnCe
Proteogenomic and targeted metabolomic analysis of ovarian cancer heterogeneity and its contribution to recurrence and therapy resistance
TArgeting Colon Tumor Initiating Cell heterogeneity
Clinical utility of tumour heterogeneity in triple negative breast cancer and high-grade serous ovarian carcinoma for prediction of therapy response
Targeting Of Resistance in PEDiatric Oncology


Projects funded under JTC 2013 on: "Translational research on tertiary prevention in cancer patients"

A randomized, 2x2 biomarker prevention trial of low-dose aspirin and metformin in colon cancer patients
Exploiting the peptidome of atypical teratoid/rhabdoid tumors - characterization of novel tumor-associated antigens for immunotherapy in order to maintain long-term remissions
Biomarkers of tumor recurrence in pancreatic cancer
MicroRNAs methylation and expression profiling for identification of breast cancer patients at high risk to develop distant metastases
A randomized phase II study for tertiary prevention of squamocellular cancer of head and neck (SCCHN) with a dietary intervention
Biomarkers related to folate-dependent one-carbon metabolism in CRC recurrence and survival
Identification of genetic markers involved in development of metastases and second cancers in melanoma
High resolution project on prognosis and CARE of cancer patients
Integrative cancer-immunology and Immunoscore for cancer classification and immunotherapies
A randomized placebo controlled phase II study with Metformin in metabolic-unbalanced breast cancer survivors at higher risk for recurrence 



Projects funded under JTC 2012 on: “Translational research on primary and secondary prevention of cancer”

An integrated approach for epigenetic risk assessment and biomarker development for breast cancer in prospective cohorts / Identifying early epigenetic predictors of breast cancer risk and their etiology determinants
Cancer prevention through improved familial risk assessment and gene discovery
New technologies for early detection of HLA loss leukemia relapse after allogeneic hematopoietic stem cell transplantation, and identification of relevant risk factors
Identification of molecular therapeutic targets and diagnostic/prognostic biomarkers for Malignant Transformation of Osteochondromas
Mesalamine for Colorectal Cancer Prevention Program in Lynch syndrome
Metabolomic profiles throughout the continuum of colorectal cancer
Nanoparticle-Enhanced molecular Fluorescence-Endoscopy for detection of early-stage colorectal adenocarcinomas
Personalized prevention of colorectal neoplasia by use of genetic variability for the prediction of efficacy and toxicity of treatment with COX-2 inhibitors and aspirin
Development of a Comprehensive Risk Prediction Model for BRCA1 and BRCA2 mutation carriers
TRanslational Implementation of Genetic Evidence in the management of MDS



Projects funded under JTC 2011 on: "Validation of biomarkers for personalised cancer medicine"

K-RAS mutations and DNA repair function in NSCLC
Circulating Tumor Cells as Biomarker for Minimal Residual Disease in Prostate Cancer
Early prediction of efficacy of endocrine therapy in breast cancer: pilot study and validation with 18F Fluoroestradiol (FES) PET/CT
Phase I clinical trial using a novel CCK-2/gastrin receptor-localizing radiolabelled peptide probe for personalized diagnosis and therapy of patiens with progressive or metastatic medullary thyroid carcinoma
Validation of immune biomarkers predictive of clinical outcome after HLA-haploidentical hematopoietic stem cell transplantation for acute leukemia
Immune Cells as Predictors for Early Diagnosis and Chemotherapy Toxicity in Ovarian Cancer
PROspective VAlidation of Biomarkers in Ewing Sarcoma for personalised translational medicine
Validation of the impact of genetic aberrations and host genetic variation in childhood acute lymphoblastic leukemia for integration into clinical practice
CD3 and CD20 lymphocytes infiltration to predict chemosensitivity in patients with triple negative breast cancer
Validation of Aprataxin as a biomarker of response to Topoisomerase I inhibitors in cancer patient

Research Infrastructures (RIs) are facilities, resources and related services that are used by the research communities to conduct research and foster innovation in their fields.

Users of Research Infrastructures can be individuals, teams and institutions from academia, business, industry and public services (*).

The European Strategy Forum on Research Infrastructures – ESFRI  (established in 2002 to support a coherent approach to policy-making on RIs in Europe),  identifies RIs of pan-European interest meeting the long-term needs of Europe’s research communities across all scientific areas.

(*) European Charter for Access to Research Infrastructures, principles and guidelines for access and related services.

Indicated below are some of the Research Infrastructures that may be of interest to researchers in the translational cancer research area.

The ESFRI landmarks (successfully implemented projects that are delivering science services or effectively advancing in their construction):

 1 bbmri logo

BBMRI ERIC: Biobanking and BioMolecular Resources Research Infrastructure

The main purpose of BBMRI-ERIC is to establish, operate and develop a pan-European distributed research infrastructure of biobanks and biomolecular resources in order to facilitate the access to resources as well as facilities and to support high quality biomolecular and medical research.
Members: Austria, Belgium, Czech Republic, Estonia, Finland, France, Germany, Greece, Italy, Latvia, Malta, the Netherlands, Norway, Poland, Sweden, and the United Kingdom.
Observer Countries: Cyprus, Switzerland, Turkey and IARC/WHO.

EATRIS ERIC: European Advanced Translational Research Infrastructure in Medicine
The EATRIS infrastructure provides researchers and companies with a support on advanced knowledge and technology that are required to boost new products through the translational maze, from target validation to early clinical trials.
Members: Latvia, Czech Republic, Denmark, Estonia, Finland, France, Italy, Luxembourg, Netherlands, Norway, Slovenia, Spain and Sweden. 

3 ECRINlogo
ECRIN ERIC: European Clinical Research Infrastructure

The main activity of ECRIN is the provision of support for the management of multinational clinical trials. Support is primarily provided during implementation, but also for preparation and protocol evaluation.
Members: France, Germany, Hungary, Italy, Norway, Portugal and Spain.
Observer Countries: Czech Republic and Switzerland. 

 4 ELIXIR logo

ELIXIR: A distributed infrastructure for life-science information
The goal of ELIXIR is to orchestrate the collection, quality control and archiving of large amounts of biological data produced by life science researchers. It coordinates, integrates and sustains bioinformatics resources across its member states and enables users in academia and industry to access vital services for their research.
Members: Belgium, Czech Republic, Denmark, EMBL-EBI, Estonia, Finland, France, Germany, Ireland, Israel, Italy, Luxembourg, Netherlands, Norway, Portugal, Slovenia, Spain, Sweden, Switzerland and UK.
Observer Country: Greece.

5 logo infrafrontier 
INFRAFRONTIER: European Research Infrastructure for the generation, phenotyping, archiving and distribution of mouse disease models

INFRAFRONTIER provides access to mouse models, data and scientific platforms and services needed to unravel the functional role of the genome in human health and disease.
Members: Germany, France, Czech Republic, Finland, Greece and the European Molecular Biology Laboratory (EMBL).
Partners: Austria; Belgium; Canada; Czech Republic; Denmark; Finland; France; Germany; Greece; Israel; Italy; Portugal; Spain; Sweden; United Kingdom, Canada.


INSTRUCT ERIC: Integrated Structural Biology Infrastructure
INSTRUCT is a distributed European infrastructure whose task is to provide peer-reviewed open access for users to a broad integrated palette of state-of-the-art structural biology infrastructure, thus promoting innovation in biomedical science and facilitating high impact research.
Members: Belgium, Czech Republic, Denmark, Germany, France, Israel, Italy, Netherlands, Portugal, Spain, Sweden and United Kingdom.

The ESFRI new projects:


EU-OPENSCREEN: European Infrastructure of Open Screening Platforms for Chemical Biology
EU-OPENSCREEN aims to progress the discovery of biologically active substances in all areas of the Life Sciences by providing transnational open access to the most advanced technologies, chemical and biological resources, and expertise and harnessing the rich chemistry knowledge of Europe in a common compound collection to advance the elucidation of the molecular mechanisms of complex biological phenomena.
Members: Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Hungary, Italy, Netherlands, Norway, Poland, Romania, Spain and Sweden.


EURO-BIOIMAGING: European Research Infrastructure for Imaging Technologies in Biological and Biomedical Sciences
Euro-BioImaging provides open physical user access to a broad range of state-of-the-art technologies in biological and biomedical imaging for life scientists. In addition, it will offer image data support and training for infrastructure users and providers.
Members: Austria, Belgium, Bulgaria, Czech Republic, Finland, France, Hungary, Israel, Italy, Norway, Poland, Portugal, Slovakia, Spain, Netherlands, United Kingdom and EMBL.

9 isbe logo 
ISBE: Infrastructure for Systems Biology Europe
The ISBE Infrastructure aims to provide interconnected centres of technological excellence in systems biology. This has the objective, via a single entity, to make available the best European research expertise – together with the experimental and modelling facilities necessary for systems biology.
Members: United Kingdom, Netherlands, Greece, Ireland, Germany, Finland, Norway, Czech Republic, Spain, Slovenia, Sweden, Italy.

 See also:


CORBEL: Coordinated Research Infrastructures Building Enduring Life-science Services
A project aimed to establish a collaborative and sustained framework of shared services between the ESFRI Biological & Medical RIs and to create a platform for harmonised user access to biological and medical technologies, biological samples and data services required by cutting-edge biomedical research. The CORBEL consortium comprises 35 individual partner institutions from 11 ESFRI Biological and Medical Sciences Research Infrastructures (BMS RI). These 11 RIs joined their scientific capabilities and services to transform the understanding of biological mechanisms and accelerate its translation into medical care.
The CORBEL Catalogue of Services is the first tool to list the main services of all these RIs at a glance and it aims to facilitate the utilisation of RI services by researchers from all over the world.

ECaDE: Early Cancer Detection Europe
The ECaDE initiative, led by EATRIS, offers support to improve the R&D pipeline specifically focused on the development of promising biomarkers for early cancer detection and differentiation of indolent from aggressive lesions. 
Members: Latvia, Czech Republic, Denmark, Estonia, Finland, France, Italy, Luxembourg, Netherlands, Norway, Slovenia, Spain and Sweden.


MERIL: Mapping the European Research Infrastructures
The MERIL database is an inventory of openly accessible research infrastructures (RIs) in Europe of more-than-national relevance across all scientific domains comprising Biological  and Medical Sciences,  Information Science and Technology.  

The launched and completed Joint Transnational Calls (JTC), in translational cancer research, are seven.


Three of them were launched and implemented under the previous TRANSCAN project:

JTC 2011  launched on December 2011 on: "Validation of biomarkers for personalised cancer medicine", 10 projects funded

JTC 2012  launched on December 2012 on: “Translational research on primary and secondary prevention of cancer”, 10 projects funded

JTC 2013  launched on December 2013 on: "Translational research on tertiary prevention in cancer patients", 10 projects funded


The ongoing TRANSCAN-2 project has launched all four calls planned:

JTC 2014 (co-funded by the European Commission)  launched on January 2015 on: "Translational research on human tumour heterogeneity to overcome recurrence and resistance to therapy", 16 projects funded

JTC 2015  launched on December 2015 on: “Immunology and immunotherapy of cancer: strengthening the translational aspects”, 7 projects funded

JTC 2016 launched on December 2016 on: "Minimally and non-invasive methods for early detection and/or progression of cancer", 14 projects funded

JTC 2017 launched on December 2017 on "Translational research on rare cancers". 12 projects funded

Page 1 of 3


 TRANSCAN-3 news:
twitter logoinkedin social media logo
 The new ERA-NET Cofund TRANSCAN-3:
 Sustained collaboration of national and regional programmes in cancer research
is funded by the European Commission under H2020  which started on 1st March 2021 and will last five years (G. A. no. 964264)

A TRANSCAN-2 brochure, highlighting key achievements, is available for download



The TRANSCAN-3 newsletters are published at:

SUBSCRIBE to the newsletters
You can unsubscribe at any moment by clicking on the subscription preferences link at the bottom of a received newsletter

All the TRANSCAN-2 newsletters:

Newsletter 10, Sept.2020
Newsletter 9, Dec.2019

Newsletter 8, May 2019
Newsletter 7, Oct.2018
Newsletter 6, June 2108
Newsletter 5, March 2018
Newsletter 4, Dec. 2017
Newsletter 3, Sept. 2017
Newsletter 2, April 2017
Newsletter 1, Dec. 2016

eu flagship

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 643638.

Who's Online

We have 17 guests and no members online